Evaluating a new imaging method for Thyroid Eye Disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the effectiveness of 18F-AlF-FAPI PET/CT in assessing the activity of Thyroid Eye Disease (TED) compared to the traditional 99mTc-DTPA SPECT/CT. Patients diagnosed with TED will undergo both imaging techniques within a 10-day period to evaluate their diagnostic accuracy and ability to assess therapy response. The study will quantify uptake in the extraocular muscles and correlate these metrics with clinical activity data to determine the superiority of the new imaging method. The goal is to enhance the diagnosis and management of TED through improved imaging techniques.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age ≥ 18 years;
2. Patients diagnosed with TED;
3. Complete understanding and voluntary participation in this study, with the signing of an informed consent form.

Exclusion Criteria:

1. Severe liver or kidney dysfunction;
2. Inability to maintain a supine position for 5 minutes to cooperate with the examination;
3. Suffering from claustrophobia or other psychiatric disorders;
4. Patients planning pregnancy or in the prenatal or lactation period;
5. Other conditions deemed unsuitable for participation in the trial by the investigator.

Where it's running

• Dept. of Nuclear Medicine, Peking University Third Hospital
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Principal investigator: Hui Li, Dr. — Peking University Third Hospital
• Study coordinator: Hui Li, Dr.
• Email: huilee1990@163.com
• Phone: 86-13121136769

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Imaging Comparison of 68Ga-FAPI and 68Ga-DOTATATE in Thyroid Eye Disease

  This study tests two PET imaging methods (FAPI and DOTATATE) to see which best images activity in the eyes of adults with thyroid eye disease.

  Recruiting Daping Hospital and the Research Institute of Surgery of the Third Military Medical University · Chongqing, Chongqing Municipality · NCT07835607

• IBI3031 in Thyroid Eye Disease (TED)

  A first-in-human test in adults with moderate-to-severe TED to see if IBI3031 is safe and tolerable when given by shot under the skin or into a vein.

  Recruiting Phase 1 Innovent Biologics (Suzhou) Co. Ltd. · Shenyang, Liaoning · NCT07622368

• AMG 732 for thyroid eye disease in a rollover, open-label study

  This study tests AMG 732 in adults with moderate-to-severe thyroid eye disease who previously did not respond or relapsed, to see if the treatment helps symptoms and is safe over a rollover period.

  Recruiting at 8 sites Phase 2 Amgen · Little Rock, Arkansas and 7 other locations · NCT07438405

• Teprotumumab N01 for adults with thyroid eye disease

  This will try Teprotumumab N01 in adults with recent-onset thyroid eye disease to see if it reduces eye inflammation and improves vision and quality of life.

  Recruiting Peking University Third Hospital · Beijing · NCT07423013

• Teprotumumab N01 vs IV steroids for active thyroid eye disease

  This trial tests whether teprotumumab N01 can help people with active thyroid eye disease better than intravenous steroids.

  Recruiting Phase 4 Innovent Biologics (Suzhou) Co. Ltd. · Shanghai, Shanghai Municipality · NCT07265258

• Testing IBI311 for inactive thyroid eye disease.

  This trial will test whether IBI311 improves eye signs and symptoms and is safe for people with inactive thyroid eye disease.

  Recruiting Phase 3 Innovent Biologics (Suzhou) Co. Ltd. · Shenyang, Liaoning · NCT07113262

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.